Natera, Inc. (NASDAQ:NTRA) Receives $140.55 Consensus PT from Brokerages

Natera, Inc. (NASDAQ:NTRA) has earned a consensus recommendation of “Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $140.55.

A number of research firms recently commented on NTRA. Canaccord Genuity restated a “buy” rating and set a $150.00 price target on shares of Natera in a research report on Monday, September 27th. BTIG Research upped their price target on shares of Natera from $155.00 to $160.00 and gave the stock a “buy” rating in a research report on Friday, August 6th. Zacks Investment Research cut Natera from a “hold” rating to a “sell” rating in a research note on Wednesday, July 28th. Robert W. Baird increased their target price on Natera from $127.00 to $145.00 and gave the company an “outperform” rating in a research note on Friday, August 6th. Finally, Piper Sandler boosted their target price on Natera from $155.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday, August 9th.

Shares of NASDAQ NTRA opened at $110.85 on Monday. The firm has a market capitalization of $10.40 billion, a price-to-earnings ratio of -30.20 and a beta of 1.26. Natera has a one year low of $65.61 and a one year high of $129.09. The business has a fifty day simple moving average of $114.57 and a 200 day simple moving average of $108.51. The company has a current ratio of 3.74, a quick ratio of 3.59 and a debt-to-equity ratio of 0.94.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 5th. The medical research company reported ($1.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.27). Natera had a negative return on equity of 74.29% and a negative net margin of 62.31%. The company had revenue of $142.03 million for the quarter, compared to the consensus estimate of $140.50 million. On average, research analysts anticipate that Natera will post -4.63 earnings per share for the current fiscal year.

In related news, CFO Michael Burkes Brophy sold 427 shares of the business’s stock in a transaction dated Thursday, September 23rd. The stock was sold at an average price of $125.67, for a total value of $53,661.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 1,649 shares of Natera stock in a transaction on Thursday, September 23rd. The stock was sold at an average price of $125.67, for a total value of $207,229.83. The disclosure for this sale can be found here. Insiders sold 226,694 shares of company stock valued at $26,247,845 over the last three months. 10.86% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Gilder Gagnon Howe & Co. LLC boosted its stake in Natera by 0.9% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 1,490,435 shares of the medical research company’s stock valued at $151,339,000 after acquiring an additional 13,262 shares during the last quarter. State Board of Administration of Florida Retirement System grew its stake in shares of Natera by 275.4% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 110,400 shares of the medical research company’s stock worth $12,534,000 after acquiring an additional 80,989 shares during the period. Chartwell Investment Partners LLC grew its stake in shares of Natera by 9.3% during the 2nd quarter. Chartwell Investment Partners LLC now owns 62,954 shares of the medical research company’s stock worth $7,147,000 after acquiring an additional 5,377 shares during the period. Envestnet Asset Management Inc. increased its holdings in Natera by 2.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 107,821 shares of the medical research company’s stock worth $12,241,000 after acquiring an additional 2,625 shares during the last quarter. Finally, Qube Research & Technologies Ltd raised its stake in Natera by 3,830.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 102,357 shares of the medical research company’s stock valued at $11,621,000 after acquiring an additional 99,753 shares during the period. Institutional investors and hedge funds own 93.97% of the company’s stock.

Natera Company Profile

Natera, Inc is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).

Further Reading: How Buying a Call Option Works

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.